Baidu
map

Am J Hum Genet:研究确定淋巴瘤的遗传风险因素

2013-09-27 佚名 生物谷

滤泡性淋巴瘤常由染色体14和18之间的易位引起,易位导致一种致癌基因BCL-2过度表达。 最近,A*STAR科学家共同领导的一个研究小组发现在这种生长缓慢的血液癌症类型中,遗传因素还扮演了另一个角色。 他们发现,免疫相关基因HLA-DRB1编码的一个氨基酸变异有助于解释为什么有些人染上疾病的风险会升高。 2009年以来,一些独立的研究小组已经发现,6号染色体短臂

滤泡性淋巴瘤常由染色体14和18之间的易位引起,易位导致一种致癌基因BCL-2过度表达。 最近,A*STAR科学家共同领导的一个研究小组发现在这种生长缓慢的血液癌症类型中,遗传因素还扮演了另一个角色。

他们发现,免疫相关基因HLA-DRB1编码的一个氨基酸变异有助于解释为什么有些人染上疾病的风险会升高。

2009年以来,一些独立的研究小组已经发现,6号染色体短臂上的基因组区域变异可以用来解释滤泡性淋巴瘤相关的部分遗传风险。

此区域包含构成人类白细胞抗原(HLA)系统的基因,HLA是免疫功能重要的介导因子。然而,科学家并不知道负责巴瘤淋风险的确切基因序列。

为了找到这些变异,人类遗传学家Jianjun Liu和他的团队与美国和欧洲科学家联手。他们在三个独立的队列人群中分析了689名滤泡性淋巴瘤患者和2,446名健康对照者的HLA基因序列。【原文下载】

所有变异都被测试,疾病关联最强的信号来自HLA-DRB1基因,一个编码HLA-DR蛋白亚单位的基因,该蛋白参与控制体内T细胞应答。

在HLA-DRB1基因序列中,Liu和他的同事发现存在6个基因变异。其中,两个基因变异与滤泡性淋巴瘤高风险相关,两个变异被列为低风险,两个变异位于高风险和低风险之间。研究人员发现,与那些携带编码低风险氨基酸的基因变异者相比,携带两个高风险变异更容易患上滤泡性淋巴瘤。

此信息可被用于鉴别患滤泡性淋巴瘤风险的高低。然而,大多数的数据来自对欧洲地区人的研究。因此,需要进一步的工作,以测试它是否也可以用于亚洲人群。

此外,研究人员表示,因为这种变异只解释一小部分的风险,进一步的研究是必要的,以确定额外的变异,此外,流行病学危险因素可能与这种遗传信息结合使用,提高临床风险预测的准确性。

原文下载

Foo JN, Smedby KE, Akers NK, Berglund M, Irwan ID, Jia X, Li Y, Conde L, Darabi H, Bracci PM, Melbye M, Adami HO, Glimelius B, Khor CC, Hjalgrim H, Padyukov L, Humphreys K, Enblad G, Skibola CF, de Bakker PI, Liu J.Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk.Am J Hum Genet. 2013 Jul 11.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733651, encodeId=76511e336518e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 05 02:21:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685908, encodeId=4d9b1685908ae, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 05 08:21:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048534, encodeId=cddc20485340d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 21 00:21:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361904, encodeId=20901361904b8, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 29 01:21:00 CST 2013, time=2013-09-29, status=1, ipAttribution=)]
    2014-03-05 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733651, encodeId=76511e336518e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 05 02:21:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685908, encodeId=4d9b1685908ae, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 05 08:21:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048534, encodeId=cddc20485340d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 21 00:21:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361904, encodeId=20901361904b8, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 29 01:21:00 CST 2013, time=2013-09-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733651, encodeId=76511e336518e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 05 02:21:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685908, encodeId=4d9b1685908ae, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 05 08:21:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048534, encodeId=cddc20485340d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 21 00:21:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361904, encodeId=20901361904b8, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 29 01:21:00 CST 2013, time=2013-09-29, status=1, ipAttribution=)]
    2013-12-21 cy0324
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733651, encodeId=76511e336518e, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Wed Mar 05 02:21:00 CST 2014, time=2014-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685908, encodeId=4d9b1685908ae, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 05 08:21:00 CST 2013, time=2013-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048534, encodeId=cddc20485340d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Dec 21 00:21:00 CST 2013, time=2013-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361904, encodeId=20901361904b8, content=<a href='/topic/show?id=651f9521535' target=_blank style='color:#2F92EE;'>#遗传风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95215, encryptionId=651f9521535, topicName=遗传风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 29 01:21:00 CST 2013, time=2013-09-29, status=1, ipAttribution=)]

相关资讯

原发性中枢神经系统淋巴瘤(PCNSL)1例报道及病例分析

  原发性中枢神经系统淋巴瘤(PCNSL)较少见,但近年来发病率逐年上升,因病变部位特殊,诊断困难,容易误诊,疗效较差,患者预后不良。本文将通过一例典型的病例介绍,对PCNSL的临床特点和诊治要点进行阐述。   病例简介   患者,男,37岁,主因“头晕,头痛,走路不稳4个月,失明失聪1个月”入院。   患者4个月前无明显诱因出现头晕,间断头痛,颞部为主,逐渐加重,并出现走路不稳、耳

JCO:分子图谱有助于外周T细胞淋巴瘤分类

据一项最新研究结果表明,高达30%的外周T细胞淋巴瘤被误诊,但如今借助分子图谱可以解决这个问题。相关的研究数据在线发表于7月15日的临床肿瘤学杂志中。(J Clin Oncol 2013 Jul 15;)T细胞淋巴瘤研究组和国际外周T细胞淋巴瘤项目的研究人员说,分子图谱可以区分血管免疫母细胞性T细胞淋巴瘤(AITL)、间变性大细胞淋巴瘤(ALCL)和非特指型(NOS)外周T细胞淋巴瘤(PTCL)。

原发性坐骨神经淋巴瘤一例

      患者 男,42岁。因右下肢麻木、疼痛1年,加重半年,于2011年4月20日在山东大学齐鲁医院血液科治疗。患者1年前无明显诱因出现右小腿屈侧疼痛,行走时疼痛明显伴右足麻木,逐渐出现右侧腓肠肌下垂无力,在当地医院诊断为腰椎间盘突出,行手术治疗,术后足部麻木感消失。术后1个月患者出现右腿短缩感;术后5个月出现右大腿背侧阵发性疼痛,触诊有电击感,屈足活动受限,肌肉僵硬,平卧

Lancet Oncol:晚期Hodgkin淋巴瘤患者的初始治疗策略

对于晚期Hodgkin淋巴瘤成人患者而言,目前存在数种治疗策略,既往所进行的研究评估过2种可供选择的治疗方案——BEACOPPescalated方案和ABVD方案对上述患者的治疗效果,但是这些研究都未能有足够权重区分这两种方案对总体生存率的影响。BEACOPPescalated方案为剂量增加的博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、丙卡巴肼和泼尼松,而ABVD

Baidu
map
Baidu
map
Baidu
map